journal article·2023-10Open access

Pentagalloyl glucose-stabilized decellularized bovine jugular vein valved conduits as pulmonary conduit replacement

Dipasha Sinha, Agnes Nagy-Mehesz, Dan Simionescu, John E. Mayer, Naren Vyavahare

Acta Biomaterialia· Volume 170

Abstract

Congenital heart diseases (CHD) are one of the most frequently diagnosed congenital disorders, affecting approximately 40,000 live births annually in the United States. Out of the new patients diagnosed with CHD yearly, an estimated 2,500 patients require a substitute, non-native conduit artery to replace structures congenitally absent or hypoplastic. Devices used for conduit replacement encounter limitations exhibiting varying degrees of stiffness, calcification, susceptibility to infection, thrombosis, and a lack of implant growth capacity. Here, we report the functionality of pentagalloyl glucose (PGG) stabilized decellularized valved bovine jugular vein conduit (PGG-DBJVC). The PGG-DBJVC tissues demonstrated mechanical properties comparable to native and glutaraldehyde fixed tissues, while exhibiting resistance to both collagenase and elastase enzymatic degradation. Subcutaneous implantation of tissues established their biocompatibility and resistance to calcification, while implantation in sheep in the pulmonary position demonstrated adequate implant functionality, and repopulation of host cells, without excessive inflammation. In conclusion, this PGG-DBJVC device could be a favorable replacement option for pediatric patients, reducing the need for reoperations required with current devices. STATEMENT OF SIGNIFICANCE: Congenital Heart Disease (CHD) is a common congenital disorder affecting many newborns in the United States each year. The use of substitute conduit arteries is necessary for some patients with CHD who have missing or underdeveloped structures. Current conduit replacement devices have limitations, including stiffness, susceptibility to infection and thrombosis, and lack of implant growth capacity. Pentagalloyl glucose-stabilized bovine jugular vein valved tissue (PGG-DBJVC) offers a promising solution as it is resistant to calcification, and biocompatible. When implanted in rats and as pulmonary conduit replacement in sheep, the PGG-DBJVC demonstrated cellular infiltration without excessive inflammation, which could lead to remodeling and integration with host tissue and eliminate the need for replacement as the child grows.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Congenital Heart Disease Studies · Cardiac Valve Diseases and Treatments · Cardiac and Coronary Surgery Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (79)

Show source-provided references
1. The changing epidemiology of congenital heart disease10.1038/nrcardio.2010.166 ↗
2. Tetralogy of Fallot, pulmonary valve replacement, and right ventricular volumes: are we chasing the right target?10.1093/eurheartj/ehv634 ↗
3. Experience with the extracardiac conduit10.1016/S0022-5223(19)38036-5 ↗
4. Right ventricle to pulmonary artery conduit reoperations in patients with tetralogy of fallot or pulmonary atresia associated with ventricular septal defect10.1016/j.amjcard.2013.01.337 ↗
5. Porcine pulmonary valve decellularization with NaOH-based vs detergent process: preliminary in vitro and in vivo assessments10.1186/s13019-018-0720-y ↗
6. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age
7. Xenograft failure of pulmonary valved conduit cross-linked with glutaraldehyde or not cross-linked in a pig to goat implantation model10.5090/kjtcs.2012.45.5.287 ↗
8. Assessment of the relationship between Contegra conduit size and early valvar insufficiency10.1016/j.athoracsur.2011.10.057 ↗
9. In search of the best xenogeneic material for a paediatric conduit: an analysis of clinical data10.1093/icvts/ivy029 ↗
10. Center for Devices and Radiological Health, (CDRH), Medtronic Contegra® Pulmonary Valved Conduit, Center for Devices and Radiological Health, e September 12, 2017.
11. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients10.1016/S1010-7940(03)00094-0 ↗
12. Failure of decellularized porcine small intestinal submucosa as a heart valved conduit10.1016/j.jtcvs.2019.09.164 ↗
13. Early failure of xenogenous de-cellularised pulmonary valve conduits–a word of caution!10.1016/j.ejcts.2010.01.044 ↗
14. A novel restorative pulmonary valve conduit: early outcomes of two clinical trials10.3389/fcvm.2020.583360 ↗
15. Initial clinical trial of a novel pulmonary valved conduit10.1053/j.semtcvs.2021.03.036 ↗
16. Stem cell therapy and tissue engineering for correction of congenital heart disease10.3389/fcell.2015.00039 ↗
17. Crosslinking strategies for preparation of extracellular matrix-derived cardiovascular scaffolds10.1093/rb/rbu009 ↗
18. Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine10.1186/s40824-023-00348-z ↗
19. Polyphenols, astringency and proline-rich proteins10.1016/0031-9422(94)85061-5 ↗
20. Tannin interactions with a full-length human salivary proline-rich protein display a stronger affinity than with single proline-rich repeats10.1016/0014-5793(96)00186-X ↗
21. Multiple interactions between polyphenols and a salivary proline-rich protein repeat result in complexation and precipitation10.1021/bi9700328 ↗
22. Pentagalloyl glucose (PGG) partially prevents arterial mechanical changes due to elastin degradation10.1007/s11340-020-00625-1 ↗
23. Elasto-regenerative properties of polyphenols10.1016/j.bbrc.2014.01.027 ↗
24. Tannic acid treatment enhances biostability and reduces calcification of glutaraldehyde fixed aortic wall10.1016/j.biomaterials.2004.04.034 ↗
25. Role of elastic fiber degradation in disease pathogenesis10.1016/j.bbadis.2023.166706 ↗
26. Extracellular matrix 4: the elastic fiber10.1096/fasebj.7.13.8405806 ↗
27. Biological and biomedical functions of Penta-O-galloyl-D-glucose and its derivatives10.1007/s11418-014-0823-2 ↗
28. Pentagalloylglucose (PGG): a valuable phenolic compound with functional properties10.1016/j.jff.2017.07.045 ↗
29. Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose10.1007/s11095-009-9932-0 ↗
30. Novel porous aortic elastin and collagen scaffolds for tissue engineering10.1016/j.biomaterials.2003.12.019 ↗
31. Biocompatibility and remodeling potential of pure arterial elastin and collagen scaffolds10.1016/j.biomaterials.2005.06.013 ↗
32. Sinha D, "Development of tissue engineered scaffolds for cardiovascular repair and replacement in pediatric patients" (2021). All Dissertations. 2940. https://tigerprints.clemson.edu/all_dissertations/2940
33. A novel crosslinking method for improved tear resistance and biocompatibility of tissue based biomaterials10.1016/j.biomaterials.2015.07.011 ↗
34. Determination of tannins by photocolorimeter
35. [14]Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent
36. Chemical stabilization of the extracellular matrix attenuates growth of experimentally induced abdominal aorta aneurysms in a large animal model10.1016/j.jvssci.2020.04.001 ↗
37. International Standard Organization, Cardiovascular implants and extracorporeal systems - Vascular prostheses - Tubular vascular grafts and vascular patches (ISO 7198:2016), 2017.
38. The suture retention test, revisited and revised10.1016/j.jmbbm.2017.08.021 ↗
39. Lu · 2005
40. Biaxial mechanical properties of bovine jugular venous valve leaflet tissues10.1007/s10237-017-0927-1 ↗
41. A nonlinear constitutive model for stress relaxation in ligaments and tendons10.1007/s10439-012-0596-2 ↗
42. Tam, H. (2016). Novel chemical crosslinking to stabilize extracellular matrix for bioprosthetic heart valve materials to resist calcification and structural degradation.
43. Fiji: an open-source platform for biological-image analysis10.1038/nmeth.2019 ↗
44. Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol
45. Tissue response to a new type of biomaterial implanted subcutaneously in rats10.1007/s00192-010-1257-3 ↗
46. Current challenges and emergent technologies for manufacturing artificial right ventricle to pulmonary artery (RV-PA) cardiac conduits10.1007/s13239-019-00406-5 ↗
47. Bovine jugular vein conduit for right ventricular outflow tract reconstruction: evaluation of risk factors for mid-term outcome10.1016/j.athoracsur.2006.04.071 ↗
48. Use of a bovine jugular vein graft with natural valve for right ventricular outflow tract reconstruction: a one-year animal study10.1016/S0022-5223(97)70149-1 ↗
49. Comparison of bovine jugular vein with pulmonary homograft conduits in children less than 2 years of age10.1016/j.ejcts.2010.01.063 ↗
50. Complete destruction of a tissue-engineered porcine xenograft in pulmonary valve position after the Ross procedure10.1016/j.jtcvs.2008.12.033 ↗
51. Decellularized biological scaffolds for cardiac repair and regeneration
52. The Sda and Cad glycan antigens and their glycosyltransferase, β1,4GalNAcT-II, in xenotransplantation10.1111/xen.12386 ↗
53. Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)10.3892/ijmm.2015.2397 ↗
54. Extracellular matrix-based biomaterial scaffolds and the host response10.1016/j.biomaterials.2016.02.003 ↗
55. The impact of detergents on the tissue decellularization process: a ToF-SIMS study10.1016/j.actbio.2016.12.033 ↗
56. Modulation of macrophage phenotype, maturation, and graft integration through chondroitin sulfate cross-linking to decellularized cornea10.1021/acsbiomaterials.8b00251 ↗
57. Antigenicity of elastin: characterization of major antigenic determinants on purified insoluble elastin10.1021/bi00533a013 ↗
58. Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells10.1016/S0003-4975(02)03649-4 ↗
59. The mechanical characterization of blood vessels and their substitutes in the continuous quest for physiological-relevant performances. A critical review
60. Structural design and mechanical performance of composite vascular grafts10.1007/s42242-022-00201-7 ↗
61. Assessing anticalcification treatments in bioprosthetic tissue by using the New Zealand rabbit intramuscular model
62. Structural requirements for stabilization of vascular elastin by polyphenolic tannins10.1016/j.biomaterials.2006.02.016 ↗
63. Right ventricular outflow tract reconstruction with an allograft conduit in non-ross patients: risk factors for allograft dysfunction and failure10.1016/j.athoracsur.2005.02.053 ↗
64. Calcification of homograft valves in the pulmonary circulation – is it device or donation related?10.1016/S1010-7940(02)00245-2 ↗
65. From cadaver harvested homograft valves to tissue-engineered valve conduits10.1016/j.ppedcard.2005.11.002 ↗
66. Application of homograft valved conduit in cardiac surgery10.3389/fcvm.2021.740871 ↗
67. Age-related enhanced degeneration of bioprosthetic valves due to leaflet calcification, tissue crosslinking, and structural changes10.1093/cvr/cvac002 ↗
68. Bioprosthetic heart valves: from a biomaterials perspective
69. Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep10.1016/j.jtcvs.2008.12.009 ↗
70. Mineralization of glutaraldehyde-fixed porcine aortic valve cusps in the subcutaneous rat model: analysis of variations in implant site and cuspal quadrants10.1002/(SICI)1097-4636(19990605)45:3<209::AID-JBM8>3.0.CO;2-N ↗
71. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats
72. Mitigation of diabetes-related complications in implanted collagen and elastin scaffolds using matrix-binding polyphenol10.1016/j.biomaterials.2012.09.081 ↗
73. Decellularized tissue-engineered heart valves calcification: what do animal and clinical studies tell us?10.1007/s10856-020-06462-x ↗
74. Stabilized collagen scaffolds for heart valve tissue engineering10.1089/ten.tea.2008.0263 ↗
75. Hsp47 as a collagen-specific molecular chaperone10.1016/B978-0-12-386471-0.00009-2 ↗
76. Roles of the endoplasmic reticulum-resident, collagen-specific molecular chaperone Hsp47 in vertebrate cells and human disease10.1074/jbc.TM118.002812 ↗
77. TGF-β1-induced HSP47 regulates extracellular matrix accumulation via Smad2/3 signaling pathways in nasal fibroblasts10.1038/s41598-019-52064-1 ↗
78. Endothelial cell control of thrombosis10.1186/s12872-015-0124-z ↗
79. Role of endothelium in thrombosis and hemostasis10.1146/annurev.med.47.1.315 ↗